Unicycive Therapeutics
Stock Forecast, Prediction & Price Target
Unicycive Therapeutics Financial Estimates
Unicycive Therapeutics Revenue Estimates
Unicycive Therapeutics EBITDA Estimates
Unicycive Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $951K 0% | $675K -29.02% | Avg: $30.94M Low: $2.06M High: $86.54M avg. 4484.47% | Avg: $238.89M Low: $18.45M High: $782.13M avg. 671.97% | Avg: $440.34M Low: $34.01M High: $1.44B avg. 84.32% | Avg: $210.01M Low: $16.22M High: $687.59M avg. -52.30% |
Net Income
% change YoY
| $-10.63M N/A | $-18.06M -69.90% | $-30.54M -69.08% | Avg: $-27.95M Low: $-19.87M High: $16.68M avg. 8.47% | Avg: $105.33M Low: $-13.25M High: $119.50M avg. 476.80% | Avg: $67.11M Low: $-13.39M High: $265.52M avg. -36.28% | Avg: $28.62M Low: $-5.71M High: $113.26M avg. -57.34% |
EBITDA
% change YoY
| $-8.97M N/A | $-18.05M -101.09% | $-30.17M -67.17% | Avg: $6.18M Low: $412.60K High: $17.30M avg. 120.50% | Avg: $47.77M Low: $3.69M High: $156.42M avg. 671.97% | Avg: $88.06M Low: $6.80M High: $288.33M avg. 84.32% | Avg: $42.00M Low: $3.24M High: $137.51M avg. -52.30% |
EPS
% change YoY
| -$0.71 N/A | -$1.2 -69.01% | -$1.28 -6.66% | Avg: -$0.25 Low: -$0.81 High: $0.68 avg. 80.46% | Avg: $2.17 Low: -$0.54 High: $4.87 avg. 966% | Avg: $2.74 Low: -$0.55 High: $10.82 avg. 26.32% | Avg: $1.17 Low: -$0.23 High: $4.62 avg. -57.34% |
Operating Expenses
% change YoY
| $8.97M N/A | $19.00M 111.68% | $21.44M 12.87% | Avg: $137.06M Low: $9.13M High: $383.33M avg. 539.04% | Avg: $1.05B Low: $81.74M High: $3.46B avg. 671.97% | Avg: $1.95B Low: $150.68M High: $6.38B avg. 84.32% | Avg: $930.23M Low: $71.86M High: $3.04B avg. -52.30% |
FAQ
What is Unicycive Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 97.91% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -19.87M, average is -27.95M and high is 16.68M.
What is Unicycive Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1297.11% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $2.06M, average is $30.94M and high is $86.54M.
What is Unicycive Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 253.86% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.81, average is -$0.25 and high is $0.68.